Clinical Trials

184 enrolled

Breast Neoplasms

NCT07420439 2026-02-19

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

108 enrolled

Lung Diseases, Interstitial

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT06690840 2026-01-05

AZALEA

45 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04765709 2025-12-16

BRIDGE

Phase 2 Terminated

10 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05583110 2025-12-10

TrasTUCAN

Phase 2 Terminated

13 enrolled

Breast Neoplasms

NCT03618550 2025-12-02

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

257 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT04759248 2025-09-09

ATREZZO

55 enrolled

Breast Neoplasms, Neoplasms

NCT06023641 2025-08-19

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

135 enrolled

Sarcoma

Rhabdomyosarcoma

NCT03482362 2025-08-03

EORTC1616

1 enrolled

Gastrointestinal

Colonic Neoplasms

NCT07001618 2025-07-23

IMMUNOLIFE2

162 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00354393 2025-07-15

Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma

Other solid neoplasmThoracic

9 enrolled

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT03414658 2025-07-02

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

100 enrolled 15 charts

Breast Neoplasms

NCT06533722 2025-06-10

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

10 enrolled

HER2-negative Metastatic Breast Cancer

NCT06377566 2025-04-20

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

71 enrolled

Lymphoid

Hodgkin Disease

NCT03242616 2025-04-17

PemVin vs Vin in Previously Treated Metastatic Breast Cancer

17 enrolled

Breast Neoplasms

NCT04296162 2025-04-17

ORCHID

178 enrolled

Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT06102824 2024-11-25

ORIENTA

252 enrolled

HER2-negative Breast Cancer

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT00309998 2024-10-29

Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

50 enrolled

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06653972 2024-10-23

EASOVCWDITHABC

Her2-negative Metastatic Breast Cancer

NCT06540950 2024-08-07

Efficacy and Safety of Concurrent Chemoradiotherapy With Oral Vinorelbine in Patients With Non-small Cell Lung Cancer

47 enrolled

Vinorelbine

NCT04922658 2024-07-31

Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

60 enrolled

Advanced Non-Small Cell Lung Cancer

NCT06229067 2024-01-29

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

182 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02709720 2024-01-11

NORA

68 enrolled 21 charts

Lung Neoplasms

NCT03620032 2023-12-06

DIPG

54 enrolled

CNS

Diffuse Intrinsic Pontine Glioma

NCT00574496 2023-09-28

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

25 enrolled 10 charts

Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

NCT00602797 2023-09-26

Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer

20 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT02585388 2023-09-06

CHEOPS

Phase 2 Terminated

120 enrolled

Breast Neoplasms

NCT04304352 2023-06-28

VEX

162 enrolled

Advanced Breast Cancer

NCT03345810 2023-06-15

DURATION

200 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00431704 2023-03-24

VinCaT

39 enrolled

Breast Neoplasms

NCT05747326 2023-02-28

Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer

Breast Neoplasms

NCT05603013 2022-11-02

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

45 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04848454 2022-10-18

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

HER2-negative Breast Cancer

NCT00887783 2022-05-17

NARLAL

117 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03801304 2022-05-12

VinMetAtezo

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04605575 2022-04-26

Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

208 enrolled

Breast Diseases, Breast Neoplasms

NCT02607215 2022-04-20

Platinum Rechallenge in Patients With Platinum-sensitive mTNBC

84 enrolled

Breast Neoplasms

NCT03254654 2022-04-20

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

66 enrolled

Advanced Triple-Negative Breast Cancer

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

100 enrolled

Triple Negative Breast Neoplasms

NCT04903652 2022-04-07

Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer

HER2-positive Advanced Breast Cancer

NCT04389073 2022-02-25

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

138 enrolled

Breast Neoplasms

NCT02139904 2021-10-12

VIM

Other solid neoplasmThoracic

154 enrolled

Mesothelioma

NCT04963595 2021-07-15

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

100 enrolled

Breast Neoplasms

NCT04922008 2021-06-10

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)

356 enrolled

Breast Neoplasms

NCT01835236 2021-03-30

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

208 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04681911 2020-12-23

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

71 enrolled